VBI Vaccines Operating Income

VBI Vaccines (VBIV) currently reports a operating income of $-71M as of March 2024. That compares with $-85M in the prior-year period — up 16.7% year over year. Use the charts on this page to explore VBI Vaccines's operating income history and peer comparisons.

VBI Vaccines's operating income increased from $-85M to $-71M — a 16.7% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

VBI Vaccines reported $-71M in operating income as of March 2024. That compares with $-85M in the prior-year period — up 16.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-71M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for VBI Vaccines, and consider following VBIV for alerts when major investors trade the stock.

VBI Vaccines is classified in the Healthcare sector. On operating income, it currently shows $-71M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VBIV with unrelated industries.